hit counter
Apellis Pharmaceuticals, Inc. (APLS) Stock News Sentiment & Price - Sentifly
APLS - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Apellis Pharmaceuticals, Inc. (APLS)

USA
Biotechnology
NASDAQ
APLS Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
APLS Latest news
Zacks Investment Research
Positive
Apellis' (APLS) Q3 Loss Widens, Revenues Surpass Estimates
2021-11-09 12:14

Apellis (APLS) reports wider-than-expected loss for the third quarter of 2021 while revenues surpass expectations.

Seeking Alpha
Neutral
Apellis Pharmaceuticals, Inc. (APLS) CEO Cedric Francois on Q3 2021 Results - Earnings Call Transcript
2021-11-08 23:38

Apellis Pharmaceuticals, Inc. (APLS) CEO Cedric Francois on Q3 2021 Results - Earnings Call Transcript

Zacks Investment Research
Positive
Apellis Pharmaceuticals, Inc. (APLS) Reports Q3 Loss, Tops Revenue Estimates
2021-11-08 18:23

Apellis Pharmaceuticals, Inc. (APLS) delivered earnings and revenue surprises of -31.79% and 143.22%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire
Neutral
Apellis Pharmaceuticals Reports Third Quarter 2021 Financial Results
2021-11-08 16:01

WALTHAM, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced its third quarter 2021 financial results and business highlights.

GlobeNewsWire
Neutral
Apellis to Present New Data Reinforcing EMPAVELI™ (pegcetacoplan) Efficacy and Safety in Patients with PNH at the 2021 ASH Annual Meeting
2021-11-04 09:17

WALTHAM, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that five abstracts were accepted for presentation at the American Society of Hematology (ASH) Annual Meeting to be held December 11-14, 2021. The new data further support the positive efficacy and safety profile of EMPAVELI, the first and only targeted C3 therapy, for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).

GlobeNewsWire
Neutral
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
2021-11-03 07:00

WALTHAM, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company will participate in the following investor conferences in November:

GlobeNewsWire
Neutral
Apellis Pharmaceuticals to Host Conference Call on November 8, 2021 to Discuss Third Quarter 2021 Financial Results
2021-11-01 07:00

WALTHAM, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company will host a conference call and webcast to discuss its third quarter 2021 financial results on Monday, November 8, 2021 at 4:30 p.m. ET.

Zacks Investment Research
Positive
Apellis Pharmaceuticals, Inc. (APLS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
2021-10-25 16:48

Apellis Pharmaceuticals, Inc. (APLS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research
Positive
Apellis (APLS) Gets CHMP Nod for Rare Blood Disorder Drug (Revised)
2021-10-21 03:50

The CHMP gives a positive opinion on and recommends granting marketing authorization to Apellis' (APLS) Aspaveli for the treatment of adults with paroxysmal nocturnal hemoglobinuria.

Zacks Investment Research
Positive
Apellis (APLS) Gets CHMP Nod for Rare Blood Disorder Drug
2021-10-18 16:42

The CHMP gives a positive opinion on and recommends granting marketing authorization to Apellis' (APLS) Aspaveli for the treatment of adults with paroxysmal nocturnal hemoglobinuria.

Loading more news...